

Urological and male genital cancers account for a considerable proportion of all human solid neoplasms and is leading to increased morbidity and mortality globally. The last decade witnessed dramatically boosted researches on urogenital cancers, some of which have profoundly impacted the diagnostic or therapeutic practice of the diseases and subsequently, sprung up intense discussions.

Since the year of 2016, the editorial board of *Translational Cancer Research* (Print ISSN: 2218-676X, Online ISSN: 2219-6803) has invited scientists across the world to write editorials and perspectives on pivotal articles that were published in some notable top journals such as *Nature*, *Cancer Cell*, *European Urology*. In this way, frontiers and progresses of urogenital cancer science were delivered to the readers, while key opinions from academic leaders were shared among the scholars worldwide.

The information explosion era has been challenging traditional reading pattern. Readers are usually too busy to screen out superior papers from numerous journals, and they do expect to acquire the viewpoints from academic elites on associated issues. Therefore, the present book aims at collecting key leaders' opinions on the latest research articles of urogenital cancers and rendering them to the readers in a friendly and readable manner. Moreover, we are delighted to see the diversity of the authors: they come from medical or academical centers of the five continents, including Johns Hopkins University School of Medicine, Mayo Clinic, Cleveland Clinic and National Cancer Institute in the USA, Heidelberg University in Germany, University of Manchester in the UK, European Institute of Oncology in Italy, Australian Prostate Cancer Research Center in Australia, Gifu University in Japan, University of Porto in Brazil, Stellenbosch University in South Africa, etc.

Content comes first! The diversity of the authors ensures the diversity of the content. The book is characterized with a variety of topics on molecular biology, detection, treatment and prognosis of the diseases, containing discussions on popular fields like precision medicine and immunotherapy, which reveals the painstaking efforts of the authors and editors.

We used to wonder that what we can do in the times of translational medicine and precision medicine. Now what we are doing on this book is making a humble contribution to the challenging era. A single spark kindles a prairie fire, and we are looking forward to enjoying the next season to this first series of *Key Leaders' Opinion on Urogenital Cancer: Frontier and Progress!*



Xinghuan Wang



Peng Zhang

**Xinghuan Wang, MD, PhD**

Professor of Urology & President,  
Zhongnan Hospital of Wuhan University, China;  
Director, Center for Evidence-Based and Translational Medicine of Wuhan University, China

**Peng Zhang, MD, PhD**

Attending Doctor of Urology,  
Zhongnan Hospital of Wuhan University, China;  
Section Editor, Editorial Board of *Translational Cancer Research*